Jim Simons Ideaya Biosciences, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 170,365 shares of IDYA stock, worth $4.41 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

170,365

Previous 109,325 55.83%

Holding current value

$4.41 Million

Previous $3.84 Million 40.62%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$30.37 - $43.05 $1.85 Million - $2.63 Million	61,040 Added 55.83%	170,365 $5.4 Million
Q2 2024 Aug 09, 2024	BUY	$34.37 - $43.46 $3.76 Million - $4.75 Million	109,325 New	109,325 $3.84 Million
Q2 2022 Aug 12, 2022	SELL	$8.28 - $13.88 $1.63 Million - $2.73 Million	-196,537 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$11.18 - $24.02 $2.2 Million - $4.72 Million	196,537 New	196,537 $2.2 Million
Q4 2021 Feb 11, 2022	SELL	$20.95 - $26.88 $620,120 - $795,648	-29,600 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$17.26 - $27.08 $673,140 - $1.06 Million	-39,000 Reduced 56.85%	29,600 $755,000
Q2 2021 Aug 13, 2021	BUY	$17.76 - $24.83 $140,304 - $196,157	7,900 Added 13.01%	68,600 $1.44 Million
Q1 2021 May 13, 2021	SELL	$13.48 - $23.77 $1.06 Million - $1.87 Million	-78,700 Reduced 56.46%	60,700 $1.43 Million
Q4 2020 Feb 10, 2021	BUY	$12.17 - $17.52 $58,416 - $84,096	4,800 Added 3.57%	139,400 $1.95 Million
Q3 2020 Nov 13, 2020	BUY	$11.22 - $14.46 $286,110 - $368,730	25,500 Added 23.37%	134,600 $1.69 Million
Q2 2020 Aug 13, 2020	BUY	$3.59 - $18.57 $391,669 - $2.03 Million	109,100 New	109,100 $1.55 Million

Others Institutions Holding IDYA

# of Institutions

215

Shares Held

80.8M

Call Options Held

69K

Put Options Held

20K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.24B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account